Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence
Frontiers in Oncology · 19.11.2025 · 15
DOI: 10.3389/fonc.2025.1672802 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 19.11.2025. Verfasst von Baolin Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with limited treatment options. Radium-223 (Ra-223) improves survival in bone-predominant mCRPC, but real-world outcomes vary widely. This meta-analysis synthesizes real-world evidence to identify prognostic factors for overall survival (OS) in Ra-223-treated patients.
Methods
Following PRISMA guidelines, we systematically searched PubMed, Embase, Web of Science, and Cochrane Library for observational studies reporting OS-associated prognostic factors in mCRPC patients receiving Ra-223. Pooled hazard ratios (HRs) were calculated. Study quality was assessed via Newcastle-Ottawa Scale.
Results
Among 25 studies (n=8,795 patients), the pooled Ra-223 completion rate was 52.6% (95% CI: 48.9–56.3%). Each additional Ra-223 injection significantly improved OS (HR = 0.478, 95% CI: 0.362–0.630). Poorer OS correlated with older age (HR = 1.012/year), higher ECOG (HR = 2.078), elevated baseline PSA (HR = 1.922), ALP (HR = 1.981), LDH (HR = 1.702), NLR (HR = 2.255), and visceral metastases (HR = 2.342). Protective factors included hemoglobin levels (HR = 0.756/g/dL) and PSA/ALP declines during therapy (HR = 0.386 and 0.701, respectively). Prior chemotherapy predicted worse outcomes (HR = 1.425), while Gleason score and concurrent bone protectants showed no significant association.
Conclusion
Real-world data confirm Ra-223’s survival benefit is closely associated with treatment completion and baseline clinical factors. The findings support risk-stratified patient selection and tailored management in mCRPC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, China.
Zitieren
APA
Song, B., Shao, H., He, Y., Zhu, X., & Qin, P. (2025). Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1672802
Vancouver
Song B, Shao H, He Y, Zhu X, Qin P. Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1672802
BibTeX
@article{Song2025,
author = {Song, Baolin and Shao, Huan and He, Yanmei and Zhu, Xinwei and Qin, Pengfei},
title = {Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer treated with radium-223: a meta-analysis of real-world evidence},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1672802}
}
EUVIMED